*Lu : Sn phm khng phi l thuc v khng dng thay th thuc tr bnh
Point mutations and NNK site saturation libraries of PtGSTF8 were constructed by overlap extension PCR as previously reported 49 using primers T7 fw, T7 term and: PtGSTF8 (V12X): V12C13_rv and V12X_fw, PtGSTF8 (C13X): V12C13_rv and C13X_fw, PtGSTF8 (C13S): V12C13_rv and C13S_fw, PtGSTF8 (N108X): N108_rv, N108X_fw, PtGSTF8 (F112X): F112_rv, F112X_fw (Supplementary Table 4) using pANT35 as template
The growth in GLP-1 drug prescriptions for Eli Lilly came during the same holiday week in which Novo Nordisk saw a decline, with its Wegovy and Ozempic GLP-1 drugs falling 4.4% and 1.6% week-over-week, respectively
The treatment duration of the trials varied from 30 to 104 weeks
The result is a vicious cycle: more triglycerides, more insulin resistance, more cardiovascular damage
It may be that we should continue treatment in people who have had cardiovascular disease, even if they dont lose as much weight as we would like. This is already the case in the United States where, in March 2024, the US Food and Drug Administration approved Wegovy to treat adults with cardiovascular disease who also have obesity or are overweight but without diabetes mellitus
